Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous Injection of Pertuzumab and Trastuzumab in Breast Cancer: A Randomized, Self-Controlled Study
NCT07533526 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2026-04-16
Summary
Research Background:Subcutaneous injection is an important route of administration in targeted therapy for breast cancer, but injection pain affects patients' treatment experience. Fluctuations in injection speed during traditional manual push may be one of the factors exacerbating pain, whereas machine-driven injection can provide a constant flow rate, theoretically reducing pain; however, high-quality evidence is lacking.
Research Objective:To compare the difference in pain intensity between instrument constant-speed injection and manual injection in breast cancer patients receiving subcutaneous injection of pertuzumab and trastuzumab.
Research Methods:A randomized self-controlled design is used, with data analysis performed using paired t-tests. The study plans to enroll 40 female breast cancer patients. Each patient receives two injection methods across two treatment cycles: instrument constant-speed injection (medical infusion pump, 2 mL/min) and manual injection (a nurse uses a stopwatch to time and simulates the injection pump speed of 2 mL/min). The order of injection methods is randomly assigned by drawing lots (the injection method for the first cycle is randomly drawn, and the method for the second cycle is naturally the alternative method). The primary outcome is the patient's most severe pain during injection, measured immediately after injection using the Numerical Rating Scale (NRS, 0-10). Secondary outcomes include injection site reactions, patient satisfaction, nurse fatigue (Borg CR10 scale), patient preference, and safety indicators.
Research Significance:The results of this study will provide high-level evidence for selecting comfortable and efficient subcutaneous injection techniques in clinical practice, thereby improving patients' treatment experience.
Conditions
Interventions
- OTHER
-
Instrument-driven constant-rate injection
Drug preparation followed the standard procedure. A fixed team of two nurses, trained according to the study protocol, performed manual injection. The nurses, after training, simulated the speed of the machine injection and recorded the actual injection time using a stopwatch. During the injection, the number of patient-reported pain episodes, immediate pain scores, and the number of times the nurse interrupted the injection due to hand fatigue were recorded. The patient's blood pressure and pulse were recorded before, during, and after the injection.
Sponsors & Collaborators
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
lead OTHER
Principal Investigators
-
Yanting Peng, Bachelor's Degree · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
-
Sun Yat-sen University · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-04-20
- Primary Completion
- 2026-10-30
- Completion
- 2026-10-30
Countries
- China
Study Locations
More Related Trials
-
Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
NCT07383818 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer
NCT07401537 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Feasibility of IRE for Early-stage Breast Cancer: a Prospective, Open-Label, Single-Arm, Exploratory Study
NCT07263451 ·Status: RECRUITING ·Phase: NA
-
Neoadjuvant Radiotherapy for Breast Cancer
NCT06313073 ·Status: RECRUITING ·Phase: NA
-
National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT]
NCT01104935 ·Status: COMPLETED ·Phase: PHASE3
-
Prospective Cohort Study of Traditional Chinese Medicine for Survival of Patients With Early Breast Cancer
NCT03797248 ·Status: UNKNOWN
-
Exclusive Intraoperative Radiation Therapy for Breast Cancer
NCT01276938 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
NCT07088263 ·Status: RECRUITING ·Phase: PHASE3
-
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
NCT04962425 ·Status: UNKNOWN
-
FMD and Neoadjuvant Chemo-immunotherapy in TNBC
NCT07378306 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer
NCT07385365 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial
NCT05165225 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer
NCT07254858 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer
NCT06733233 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC
NCT07523789 ·Status: NOT_YET_RECRUITING
-
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
NCT04262804 ·Status: UNKNOWN ·Phase: PHASE2
-
Pre-operative Therapy in Breast Cancer
NCT05621564 ·Status: RECRUITING
-
Minimally Invasive Biopsy Predicting Breast pCR After NAC for Breast Cancer
NCT03789851 ·Status: UNKNOWN ·Phase: NA
-
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
NCT07393425 ·Status: RECRUITING ·Phase: PHASE2
-
Response-Based Local Therapy for Regionally Advanced Breast Cancer
NCT07376538 ·Status: RECRUITING ·Phase: PHASE2
-
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC
NCT04609540 ·Status: UNKNOWN
-
A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Premenopausal Breast Cancer Patients
NCT03543059 ·Status: UNKNOWN
-
Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index
NCT05728268 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
NCT07351487 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.
NCT03735966 ·Status: COMPLETED ·Phase: PHASE2